AVE3085 Protects Coronary Endothelium from the Impairment of Asymmetric Dimethylarginine by Activation and Recoupling of eNOS.

Purpose: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of eNOS and it is recognized as a risk factor for endothelial dysfunction in cardiovascular diseases. We investigated the effect of AVE3085, a newly developed transcription enhancer of eNOS, on ADMA-induced endothelial dysfunction in coronary arteries with underlying mechanisms explored. Methods: Porcine coronary small arteries (diameter 600-800 μm) were studied in a myograph for endothelium-dependent relaxation to bradykinin and endothelium-independent relaxation to sodium nitroprusside. Protein expressions of eNOS and phosphorylated-eNOS (p-eNOS and p-eNOS), and nitrotyrosine formation were determined by Western blot. NO release was directly measured with a NO microsensor. Productions of O and peroxynitrite (ONOO) were determined by lucigenin- and luminol- enhanced chemiluminescence respectively. Results: Exposure to ADMA significantly decreased the bradykinin-induced vasorelaxation and reduced the protein expression of p-eNOS whereas increased the expression of p-eNOS and nitrotyrosine. Pre-incubation with AVE3085 restored the bradykinin-induced relaxation, reversed the decrease of p-eNOS, and lowered the level of p-eNOS and nitrotyrosine. NO release in response to bradykinin was significantly reduced by ADMA and such reduction was restored by AVE3085. AVE3085 also prevented the elevation of O and ONOO levels in coronary arteries exposed to ADMA. Conclusions: AVE3085 prevents ADMA-induced endothelial dysfunction in coronary arteries. The protective effect of AVE3085 may be attributed to increased NO production resulting from enhanced eNOS activation, and decreased oxidative stress that involves inhibition of O generation by eNOS recoupling. The present study suggested the therapeutic potential of AVE3085 in endothelial dysfunction in cardiovascular disorders. [ABSTRACT FROM AUTHOR]